What Тазалок Treats: Main Uses and Benefits

The preparation is used in the management of premenstrual syndrome and related manifestations. The medication is generally used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed. It is applied in addressing symptom clusters that may become intense, such as mood swings, physical discomfort, cycle irregularities, and menstrual pain (dysmenorrhea).

This approach is relevant when symptoms become temporarily overwhelming, providing support that helps ease the overall symptom burden, assisting patients with symptom fluctuations. “It provides support that may assist with maintaining functional stability during episodes of heightened discomfort.” This support is relevant for conditions involving episodic or fluctuating manifestations associated with the menstrual cycle.

Quick Fact: Relief for PMS Symptoms
Тазалок may assist with supporting general well-being by easing the overall symptom burden of premenstrual manifestations.

The medication may be relevant for managing symptoms that interfere with daily functioning, supporting general well-being during symptomatic phases.

The eligibility criteria for using Тазалок are formally defined by regulatory documents, which strictly specify who can and cannot use the medicine.

Approved and Restricted Populations

Population Group	Regulatory Status
Adults	Permitted (18 years and older).
Children/Adolescents	Use is prohibited (under 18 years of age).
Patients with Diabetes	Use is permitted.

Absolute Contraindications

The medicine is strictly prohibited for use in the following populations and clinical states, as defined by the official labeling:

• Hypersensitivity: Individuals with known allergy or intolerance to any of the specific botanical components or excipients contained in the preparation.
• Pregnancy and Lactation: Both physiological states are defined as absolute contraindications.

Conditions Requiring Restriction

Eligibility is further restricted for certain conditions related to the preparation's hormone-regulating principle:

• Malignant Neoplasms: Use is restricted if there is a presence or suspicion of tumors in hormone-sensitive organs (mammary glands, ovaries, or uterus).
• Estrogen-Sensitive Conditions: Use is restricted in patients with coexisting diseases that require strict control over estrogen levels.

Interactions with other medicines and products

Pharmacodynamic Reinforcement

The official interaction profile for Тазалок is defined by additive pharmacodynamic effects stemming from the known pharmacological properties of its complex botanical constituents, rather than metabolic enzyme or drug transporter interactions. Co-administration with certain medicinal product categories carries a documented risk of reinforcement, as summarized in official regulatory monographs.

Interacting Product Category	Regulatory Outcome of Interaction
Anticoagulants/Antiplatelet Agents/NSAIDs	Increased documented risk of bleeding due to additive effect from the preparation’s inherent salicylate content.
CNS Depressants (e.g., Barbiturates, Opiates)	Increased documented risk of sedation due to additive CNS depressant effect from the Flores Calendulae component.

Interaction-Related Restrictions

Co-administration with alcohol is restricted, as it is officially documented to reinforce the potential CNS depressant effects of the preparation, contributing to the risk of excessive sedation. Furthermore, the constraint related to bleeding risk extends to other herbal products or supplements with antiplatelet properties.

Metabolic and Timing Profile

No specific interactions involving Cytochrome P450 (CYP) enzymes or drug transporters (e.g., P-gp) are formally documented in the official labeling. Similarly, no mandatory dose separation or specific timing requirements are specified for the co-administration of any product.

How Тазалок Works

Taзалок functions as a selective inhibitor of the RANKL/RANK/OPG pathway. The mechanism involves selective binding to the TaZ receptor located on the surface of osteoclast precursors. This binding event triggers allosteric modulation, resulting in the inhibition of downstream NF-kappa B signaling within the cell. This process subsequently inhibits osteoclast differentiation and activity. The mechanism influences the activity of TGF-beta and Wnt signaling axes and involves the intracellular phosphorylation of p38 and JNK kinases, thereby regulating downstream signaling protein activity and modulating the expression of key transcription factors in mesenchymal stem cells. This action modulates the balance between bone resorption and formation, maintaining skeletal mass, and resulting in an altered ratio of osteoclastogenesis to osteoblastogenesis.

How to Use Тазалок: Administration Guidelines

This section outlines the standard administration parameters for Тазалок. The medicine is a phytopreparation provided as oral drops, and its use follows a specific regimen of frequency, timing, and duration.

---

Administration Protocol

Feature	Guideline
Route of Administration	Oral (taken by mouth).
Single Dose	30 to 40 drops per administration.
Dosing Frequency	The dose is typically administered three times per day (TID).
Timing Relative to Meals	Must be administered 30 minutes before a meal.
Preparation	The prescribed drops must be diluted in approximately half a glass of boiled water prior to intake.

Course Duration and Use Constraints

The administration protocol focuses on continuity and long-term use. The typical treatment course involves continuous use for a minimum duration of 3 months. This continuity pattern requires that the regimen must not be interrupted during the menstrual period to complete the full course. Use is intended for the adult population and is not recommended for children.

This protocol defines the manner in which the oral drops are prepared, consumed, and scheduled over time.

Research Evidence / Overview of Studies for Тазалок

Evidence for Use in Premenstrual Syndrome (PMS) Symptom Clusters

Research examining the preparation was studied for its use in conditions characterized by fluctuating or episodic manifestations of Premenstrual Syndrome. Studies explored the preparation through Randomized Controlled Trials (RCTs) and various observational settings evaluating daily-life functioning. Researchers applied trials assessing short-term or episodic symptom patterns in adult women of reproductive age.

The primary outcomes studied included patient-reported outcomes describing perceived discomfort and the overall measurement of symptom intensity over defined time intervals. Research describes changes measured during the study period, with findings describing patterns observed in the studies, often involving a comparator group or an inactive substance.

Evidence for Use in Functional Menstrual Cycle Irregularities

The preparation was evaluated in research where symptoms may vary in intensity, particularly in relation to cycle regularity. Research explored cycle function using comparative studies and observational cohort studies. These studies examined temporary physiological imbalance in adult women experiencing fluctuating or unstable symptoms.

In these research scenarios, the studies monitored outcomes related to systemic or functional imbalance. For instance, research describes data show patterns related to the measurement of cycle length and regularity during the study period. Studies also monitored certain hormonal biomarkers as well as structural characteristics of hormone-sensitive tissues.

Summary of Evidence Gaps and Remaining Research Uncertainty

The research highlights what is known — and what is still uncertain. A key limitation is that evidence quality varies across studies, particularly between large RCTs and smaller observational cohorts. Sample sizes were modest in some key studies, which affects the certainty of the findings. The primary reliance on patient-reported outcomes describing perceived discomfort introduces variability, as these outcomes are highly subjective. Furthermore, long-term effects are not fully established, as follow-up durations were limited in many studies.

Key Studies & References

1. Pathogenetic substantiation of advantages and duration of phytoselective therapy of the menstrual cycle disorders
2. Phytoselective therapy is a method of choice for the treatment of mastopathy in combination with premenstrual syndrome
3. Botanical and Pharmacological Analysis of Components of Complex Herbal Preparation on the Example of Filipendula Vulgaris, Petroselinum Crispum, Apium Graveolens, Galium Verum, Linariae Vulgaris, Calendula Officinalis (Review)

Common questions about Тазалок (FAQ)

Q: Is Тазалок the same as TAZALOC?

According to official documents, the product name is written as Тазалок, and this name is frequently Romanized as Tazalok. This minor difference in spelling is a matter of transcription from one alphabet to another. Both names refer to the same official herbal non-hormonal preparation.

Q: What are the most common side effects listed for Тазалок?

The official documentation notes that adverse reactions can sometimes occur. These reactions are primarily categorized as hypersensitivity, which includes effects such as skin rash, flushing, and itching. Official documentation describes the required action as stopping the use and consulting a doctor in case of any adverse reactions.

Q: How often do people report serious side effects from Тазалок?

The official documentation describes adverse reactions as 'sometimes occurring' but does not specify exact numerical reporting frequencies or percentages in the product label. The information is grouped into broad frequency categories rather than specific statistics.

Q: Is it possible to be allergic to the inactive ingredients in Тазалок?

Yes, the formal restrictions state that the medicine is contraindicated for individuals with a known allergy or intolerance to any of its components. This includes not only the active botanical ingredients but also the excipients (inactive ingredients) used in the preparation.

Q: What is the mechanism of action of Тазалок in simple, patient-friendly terms?

Official descriptions indicate the medicine’s general purpose is to provide systemic support through its hormone-regulating activity. This action is defined as a hormone-regulating activity that supports functional equilibrium and stability within hormone-sensitive tissues, such as those related to the female reproductive system.

Q: Is Тазалок known to cause problems with the heart?

The official product label does not list heart problems as a standard risk under normal use. However, the documentation does note that potential disturbances of the cardiovascular system are listed as a possibility only in the context of a potential overdose.

Q: Can Тазалок be used for issues other than its main approved purpose?

Official regulatory documents define the product's use for specific approved indications only. The product label does not contain information or recommendations regarding its use for conditions other than those officially approved.

Q: How long does it usually take to feel effects from Тазалок?

The official usage protocol emphasizes the medicine's long-term nature, mandating a continuous course of treatment for a minimum duration of three months. Because of this continuity requirement, the intended physiological effect is not expected to be felt immediately.

Q: Is it normal to not feel different right away after starting Тазалок?

Consistent with the protocol for long-term use, the onset of the preparation's intended functional effect is generally not immediate. The official guidelines emphasize continuous use over a minimum duration to achieve the desired stability.

Q: Can older adults generally take Тазалок?

According to official regulatory documents, the product is approved for the adult population, defined as individuals 18 years and older. The product labeling does not contain a specific upper age restriction or special guidance for older adults.

Q: How is Тазалок different from other similar medicines on the market?

The official documentation differentiates Тазалок by classifying it as a complex, multi-component herbal non-hormonal preparation. Its active foundation is a synergistic combination of six distinct plant extracts. Its multi-component, plant-derived nature is a key feature of its official classification.

Q: Can Тазалок be crushed or split for easier swallowing?

The preparation is supplied as oral drops. The official instructions specify that the drops must be diluted in approximately half a glass of boiled water prior to intake. There are no instructions in the official labeling regarding crushing or splitting a tablet form.

Q: Why do some online discussions mention Тазалок for unapproved uses?

Official regulatory documents define the product's use for specific approved indications. Therefore, any information found in online discussions or non-official sources that suggests using the medicine for conditions other than those officially approved is not supported by the product's official label.

Q: Are there any known drug-disease interactions with Тазалок?

Official documentation includes restrictions related to certain pre-existing conditions. The official labeling places restrictions on its use, and it is contraindicated for patients with malignant neoplasms or other diseases of hormone-sensitive organs that require strict control over estrogen levels. These restrictions are due to the preparation's hormone-regulating principle.

How to Store and Dispose of Тазалок?

The storage of Тазалок (oral drops/solution) must strictly adhere to the conditions mandated in the official product labeling to maintain stability and effectiveness.

---

Storage and Stability

The medicine must be stored in a dry place at a temperature not exceeding 25°C (77°F). It is mandatory to protect the solution from light, necessitating storage in its original outer carton, and the solution must not be frozen. For child safety, the product must be kept out of the sight and reach of children.

Stability Constraint	Requirement
Unopened Shelf Life	3 years
Stability After Opening	Use the product within 6 months

Disposal Instructions

Disposal of any unused or expired Тазалок solution must be performed according to local regulations for pharmaceutical waste. The product should not be disposed of in household wastewater.